Fig. 1



PPMX2016
(Mouse)
Percent of inhibition (%)
100
75
50
25
0
1.1 uM
0.001
0.01
0.1
1
10
100
Antibody concentration (μg/mL)
PPAT-052-27c
(Chimera)
Percent of inhibition (%)
100
75
50
25
0
1.1 uM
0.001
0.01
0.1
1
10
100
1000
Antibody concentration (μg/mL)

Fig. 2



PPMX2016 (antibody : chelating agent 1:10) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Spleen
Pancreas
Kidneys
Stomach
Small Intestine
Large intestine
Muscle
Bone
Skin
Tumor

Fig. 3



PPMX2016 (antibody : chelating agent 1:3) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Pancreas
Spleen
Kidneys
Small Intestine
Large intestine
Muscle
Bone
Tumor

Fig. 4



PPMX2029 (antibody : chelating agent 1:10) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Spleen
Pancreas
Kidneys
Stomach
Small Intestine
Large intestine
Muscle
Bone
Skin
Tumor

Fig. 5



PPMX2029 (antibody : chelating agent 1:3) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Pancreas
Spleen
Kidneys
Small Intestine
Large intestine
Muscle
Bone
Tumor

Fig. 6



PPMX2025 (antibody : chelating agent 1:10) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Spleen
Pancreas
Kidneys
Stomach
Small Intestine
Large intestine
Muscle
Bone
Skin
Tumor

Fig. 7



PPMX2025 (antibody : chelating agent 1:3) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Pancreas
Spleen
Kidneys
Small Intestine
Large intestine
Muscle
Bone
Tumor

Fig. 8




Fig. 9



PPAT-052-27c (antibody : chelating agent 1:3) 96 hours after administration
%ID/g
35
30
25
20
15
10
5
0
Blood
Lung
Heart
Liver
Pancreas
Spleen
Kidneys
Small Intestine
Large intestine
Muscle
Bone
Tumor

Fig. 10



PPAT-052-27c (antibody : chelating agent 1:3) 48 hours after administration
%ID/g
60
50
40
30
20
10
0
Blood
Liver
Spleen
Kidney
Bone
Tumor

Fig. 11




PPAT-052-28c (antibody : chelating agent 1:3)
48 hours after administration
96 hours after administration
%ID/g
60
50
40
30
20
10
0
Blood
Liver
Spleen
Kidney
Bone
Tumor

Fig.12


NCI-H358 xenograft growth
Tumor volume (mm3)
Days after treatment
0
200
400
600
800
1000
1200
1400
0
10
20
30
40
50
60
Saline
PPMX2029-200 μCi
PPMX2029-150 μCi
PPMX2029-100 μCi
PPMX2029-50 μCi
PPMX2029




NCI-H1373 xenograft growth
PPAT-052-27c 150 μci
PPAT-052-27c 100 μci
PPAT-052-27c
Saline
Tumor Volume(mm3)
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
Days after treatment

Fig. 13

Fig. 14


negative control
anti-CDH3 antibody
Lung cancer
Lung cancer
Colorectal cancer
Colorectal cancer
Pancreatic cancer